阿里健康(00241.HK)附屬擬向來未來科技注資2.16億元並轉讓熙牛醫療80%股權
格隆匯9月23日丨阿里健康(00241.HK)發佈公告，於2020年9月23日，阿里健康北京及弘雲久康（均為公司附屬公司）與目標公司來未來科技（浙江）有限公司、目標創始人及現有目標股東訂立增資協議，據此，阿里健康北京將以現金向目標公司注資人民幣2.16億元；及弘雲久康將透過向目標公司轉讓熙牛醫療80%股權，向目標公司作出相等於人民幣2880萬元的實物出資。緊隨增資協議交割後，目標公司的註冊資本應增至人民幣1957萬元，屆時目標公司將分別由阿里健康北京及弘雲久康持有26.47%及3.53%。
同日，弘雲久康與目標公司訂立股權轉讓協議，據此，弘雲久康須向目標公司轉讓熙牛醫療80%股權，以作為增資協議項下的實物出資。緊隨股權轉讓協議交割後，熙牛醫療將分別由目標公司及上海羽雋持有80%及20%。
目標公司為2020年1月於中國成立的有限責任公司，主要從事企業智能平台業務。於本公告日期，現有目標股東於目標公司持股比例為100%。
熙牛醫療為2017年12月於中國成立的有限責任公司，其主要業務是利用雲計算、大數據、人工智慧及其他技術，以人類健康為目標發展創新醫療產品、服務及解決方案。目前已成功開發出用於大型醫療集團及醫聯體的基於人工智慧的雲醫院資訊平台產品，該產品已在兩個院區進入試運營階段，並開發出以覆蓋區域所有醫療機構全量業務數位化為重點的區域智慧健康雲平台。
公司表示，目標公司的創始人及經營者均為企業智慧平台專家，於開發及管理複雜資訊系統方面具備豐富經驗及備受認可的專業知識，其業務潛能已獲得投資者認可。集團認為，目標公司的經驗及專業知識極利於熙牛醫療持續發展於醫療領域的產品及計劃，為拓展全國業務奠定堅實基礎。集團通過引導目標公司發展及建設支持熙牛醫療產品的技術基礎設施，將通過生態合作的方式達成“1+1>2”的效益，令中國醫療市場及其參與者受惠。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
